Granted Patent B2

US 10,544,399 · App. 15/928,385 · Granted Jan 28, 2020

Inventors: Gale Smith (Germantown, MD); Yingyun Wu (Clarksburg, MD); Michael J. Massare (Mt. Airy, MD); Peter M. Pushko (Frederick, MD); Margaret Nathan (Montgomery Village, MD); Thomas Kort (Germantown, MD); Robin Robinson (Dickerson, MD)

Assignee: Novavax, Inc.

C12N7/00A61K39/12C07K14/005C12N9/2402C12Y302/01018A61K2039/5258A61K2039/55505A61K2039/55555C07K2319/01C07K2319/03C12N2710/14143C12N2760/16122C12N2760/16123C12N2760/16134C12N2760/16151C12N2760/16171C12N2760/16222C12N2760/16223C12N2760/16251C12N2770/20022C12N2770/20023C12N2770/20051C12N2800/22

Abstract

Claims (20)

1. A virus-like particle (VLP) comprising influenza proteins, wherein the influenza proteins consist of an influenza M1 protein and an influenza hemagglutinin (HA) protein, wherein said M1 protein comprises the amino acid residues YKKL at the positions corresponding to positions 100-103 of SEQ ID NO: 49.

2. The VLP of claim 1 , wherein said influenza M1 protein is derived from an avian influenza virus strain.

3. The VLP of claim 2 , wherein said avian influenza virus strain is A/Indonesia/5/05.

4. The VLP of claim 1 , wherein the HA protein is from a different influenza strain than the M1 protein.

5. The VLP of claim 4 , wherein said HA protein is derived from an avian influenza virus.

6. The VLP of claim 5 , wherein said avian influenza virus is H5N1.

7. The VLP of claim 5 , wherein said avian influenza virus is H9N2.

8. The VLP of claim 4 , wherein said HA protein is derived from a seasonal influenza virus.

9. The VLP of claim 8 , wherein said seasonal influenza virus is a type A influenza virus.

10. The VLP of claim 8 , wherein said seasonal influenza virus is a type B influenza virus.

11. The VLP of claim 4 , wherein said HA protein exhibits hemagglutinin activity.

12. The VLP of claim 4 , wherein said HA protein is a chimeric protein.

13. The VLP of claim 12 , wherein said chimeric proteins comprise external domains of non-avian influenza HA protein sequences fused to the transmembrane and/or cytoplasmic terminal domains of the avian HA.

14. The VLP of claim 13 , wherein said non-avian influenza HA is from influenza strain A/Wisconsin/67/2005 and said avian influenza HA is from influenza strain A/Indonesia/5/05.

15. A method of increasing the efficiency of VLP production comprising expressing an influenza M1 protein and an influenza hemagglutinin (HA) protein in an insect host cell, wherein said M1 protein comprises the amino acid residues YKKL at the positions corresponding to positions 100-103 of SEQ ID NO: 49, wherein the influenza proteins consist of an influenza M1 protein and an influenza hemagglutinin (HA) protein.

16. The method of claim 15 , wherein said influenza M1 protein is derived from an avian influenza virus strain.

17. The method of claim 16 , wherein said avian influenza virus strain is A/Indonesia/5/05.

18. The method of claim 15 , wherein the HA protein is from a different influenza strain than the M1 protein.

19. The VLP of claim 18 , wherein said HA protein is derived from a seasonal influenza virus.

20. A vaccine comprising the VLP of claim 1 .

Assignments (2)

Continuity (18)